Rankings
▼
Calendar
MESO Q2 2024 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena
MESO
Mesoblast Limited
$2B
Q2 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
-14.4% YoY
Gross Profit
-$8M
-472.4% margin
Operating Income
-$20M
-1184.6% margin
Net Income
-$16M
-960.4% margin
EPS (Diluted)
$-0.19
QoQ Revenue Growth
+0.0%
Cash Flow
Operating Cash Flow
-$13M
Free Cash Flow
-$13M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$670M
Total Liabilities
$162M
Stockholders' Equity
$509M
Cash & Equivalents
$77M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$2M
-14.4%
Gross Profit
-$8M
-$14M
+41.1%
Operating Income
-$20M
-$21M
+5.0%
Net Income
-$16M
-$24M
+33.6%
← FY 2024
All Quarters
Q3 2024 →